HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity

Toxicology and Applied Pharmacology

Volumn 262, Issue 1, 2012, Pages 1-10

  Reynolds, Joseph G ^a   Geretti, Elena ^a   Hendriks, Bart S ^a   Lee, Helen ^a   Leonard, Shannon C ^a   Klinz, Stephan G ^a   Noble, Charles O ^a   Lücker, Petra B ^b   Zandstra, Peter W ^b   Drummond, Daryl C ^a   Olivier, Kenneth J ^a   Nielsen, Ulrik B ^a   Niyikiza, Clet ^a   Agresta, Samuel V ^a   Wickham, Thomas J ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiotoxicity; Doxorubicin; HER2 targeted liposomal doxorubicin; Preclinical safety; Safety sciences; Stem cell derived cardiomyocytes

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, NUDE; MYOCYTES, CARDIAC; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84861757024     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.04.008     Document Type: Article

References (26)

1. Bauwens C.L., Song H., Thavandiran N., Ungrin M., Masse S., Nanthakumar K., Seguin C., Zandstra P.W. Geometric control of cardiomyogenic induction in human pluripotent stem cells. Tissue Eng. Part A. 2011, 17:1901-1909.
2. Chia S., Clemons M., Martin L.A., Rodgers A., Gelmon K., Pond G.R., Panasci L. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J. Clin. Oncol. 2006, 24:2773-2778.
3. Chien K.R. Herceptin and the heart-a molecular modifier of cardiac failure. N. Engl. J. Med. 2006, 354:789-790.
4. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
5. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., Lenihan D.J. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 2005, 23:7820-7826.
6. Eytan G.D., Kuchel P.W. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cytol. 1999, 190:175-250.
7. Feldman A.M., Lorell B.H., Reis S.E. Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. Circulation 2000, 102:272-274.
8. Fuchs I.B., Landt S., Bueler H., Kuehl U., Coupland S., Kleine-Tebbe A., Lichtenegger W., Schaller G. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res. Treat. 2003, 82:23-28.
9. Gianni L., Salvatorelli E., Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc. Toxicol. 2007, 7:67-71.
10. Hendriks, B., S, Reynolds, J. G., Klinz, S., Eckelhofer, I., Geretti, E., Lee, H., Leonard, S., Espelin, C., Agresta, S., and Wickham, T., submitted for publication.
11. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66:6732-6740.
12. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
13. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
14. Liu J., Mao W., Ding B., Liang C.S. ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1956-H1965.
15. Lu W.L., Qi X.R., Zhang Q., Li R.Y., Wang G.L., Zhang R.J., Wei S.L. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J. Pharmacol. Sci. 2004, 95:381-389.
16. Millard B.L., Niepel M., Menden M.P., Muhlich J.L., Sorger P.K. Adaptive informatics for multifactorial and high-content biological data. Nat. Methods 2011, 8:487-492.
17. Nellis D.F., Ekstrom D.L., Kirpotin D.B., Zhu J., Andersson R., Broadt T.L., Ouellette T.F., Perkins S.C., Roach J.M., Drummond D.C., Hong K., Marks J.D., Park J.W., Giardina S.L. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Prog. 2005, 21:205-220.
18. Nellis D.F., Giardina S.L., Janini G.M., Shenoy S.R., Marks J.D., Tsai R., Drummond D.C., Hong K., Park J.W., Ouellette T.F., Perkins S.C., Kirpotin D.B. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog. 2005, 21:221-232.
19. Neve R.M., Nielsen U.B., Kirpotin D.B., Poul M.A., Marks J.D., Benz C.C. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Commun. 2001, 280:274-279.
20. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K., Park J.W., Refaat Shalaby M., Shao Y., Benz C.C., Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 2002, 1591:109-118.
21. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., Catane R., Kieback D.G., Tomczak P., Ackland S.P., Orlandi F., Mellars L., Alland L., Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15:440-449.
22. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
23. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
24. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
25. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., Muggia F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 1979, 91:710-717.
26. Yang L., Soonpaa M.H., Adler E.D., Roepke T.K., Kattman S.J., Kennedy M., Henckaerts E., Bonham K., Abbott G.W., Linden R.M., Field L.J., Keller G.M. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008, 453:524-528.